TP53 and Miyoshi myopathy: AZD7762, a Chk1/2 inhibitor, potentiates DNA-damaging agents such as bendamustine, melphalan, and doxorubicin in p53-mutated MM by abrogating checkpoint-mediated arrest and promoting apoptosis (37).